Devyser Diagnostics Past Earnings Performance
Past criteria checks 0/6
Devyser Diagnostics's earnings have been declining at an average annual rate of -23.3%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 25.2% per year.
Key information
-23.31%
Earnings growth rate
-17.02%
EPS growth rate
| Biotechs Industry Growth | 0.71% |
| Revenue growth rate | 25.21% |
| Return on equity | -13.52% |
| Net Margin | -19.44% |
| Next Earnings Update | 05 Nov 2025 |
Recent past performance updates
Recent updates
Devyser Diagnostics AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jul 25
Revenues Tell The Story For Devyser Diagnostics AB (publ) (STO:DVYSR) As Its Stock Soars 31%
Jul 23Optimistic Investors Push Devyser Diagnostics AB (publ) (STO:DVYSR) Shares Up 27% But Growth Is Lacking
May 10Devyser Diagnostics AB (publ) (STO:DVYSR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 02Companies Like Devyser Diagnostics (STO:DVYSR) Are In A Position To Invest In Growth
Apr 09Devyser Diagnostics AB (publ) (STO:DVYSR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Feb 17Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts
Jun 14Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company
Mar 20Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates
Feb 23Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business
Feb 22Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company
Dec 09These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts
Aug 30Devyser Diagnostics AB (publ) (STO:DVYSR) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 14Revenue & Expenses Breakdown
How Devyser Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 25 | 235 | -46 | 196 | 31 |
| 31 Mar 25 | 221 | -70 | 199 | 39 |
| 31 Dec 24 | 217 | -61 | 193 | 43 |
| 30 Sep 24 | 198 | -71 | 187 | 45 |
| 30 Jun 24 | 196 | -54 | 178 | 45 |
| 31 Mar 24 | 181 | -46 | 169 | 37 |
| 31 Dec 23 | 169 | -54 | 164 | 38 |
| 30 Sep 23 | 158 | -57 | 165 | 34 |
| 30 Jun 23 | 143 | -60 | 157 | 31 |
| 31 Mar 23 | 136 | -60 | 146 | 33 |
| 31 Dec 22 | 127 | -46 | 132 | 26 |
| 30 Sep 22 | 117 | -40 | 115 | 23 |
| 30 Jun 22 | 110 | -35 | 103 | 22 |
| 31 Mar 22 | 101 | -27 | 90 | 18 |
| 31 Dec 21 | 93 | -21 | 76 | 18 |
| 31 Dec 20 | 66 | -11 | 42 | 17 |
| 31 Dec 19 | 64 | 7 | 34 | 7 |
| 31 Dec 18 | 48 | 1 | 30 | 7 |
Quality Earnings: DVYSR is currently unprofitable.
Growing Profit Margin: DVYSR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DVYSR is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.
Accelerating Growth: Unable to compare DVYSR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DVYSR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (51.4%).
Return on Equity
High ROE: DVYSR has a negative Return on Equity (-13.52%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/05 11:49 |
| End of Day Share Price | 2025/08/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Devyser Diagnostics AB (publ) is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Erik Hultgård | DNB Carnegie |
| Ludvig Lundgren | Nordea Markets |